Dai Chun-Hua, Li Jian, Yu Li-Chao, Li Xia-Qin, Shi Shun-Bing, Wu Jian-Rong
Department of Medical Oncology, Affiliated Hospital of Jiangsu University, Zhenjiang, China.
Tumour Biol. 2013 Apr;34(2):1245-53. doi: 10.1007/s13277-013-0667-5. Epub 2013 Jan 26.
Lymph node metastasis is a major prognostic factor in resected non-small cell lung cancer (NSCLC). However, 30-40 % rate of recurrence after performing complete resection in node-negative patients suggests that their nodal staging is suboptimal. We aimed to evaluate the molecular diagnosis and prognostic significance of lymph node micrometastasis in patients with node-negative NSCLC. Primary tumor samples from 62 patients with resected stage I-IIB NSCLC were screened for fragile histidine triad (FHIT) and CDKN2A mRNA deletion using reverse transcriptase polymerase chain reaction (RT-PCR). The molecular alternations were found in tumors of 49 patients. A total of 269 lymph nodes from these 49 NSCLC patients with FHIT or/and CDKN2A deletion tumors were examined. Fifteen positive-control nodes and ten negative-control nodes were also analyzed for FHIT and CDKN2A mRNA deletion. Thirty-nine (22 %) and 22 (18 %) lymph nodes from the 49 patients with FHIT and CDKN2A mRNA deletion in primary tumor had FHIT and CDKN2A mRNA deletion, respectively. The types of FHIT and CDKN2A mRNA deletion in lymph nodes were identical with those in their primary tumors. By combination of two markers, 16 patients (32.7 %) were found to have nodal micrometastasis. Survival analysis showed that patients with nodal micrometastasis had reduced disease-free survival (P = 0.001) and overall survival (P = 0.002) rates. Multivariate analysis demonstrated that nodal micrometastasis was an independent predictor for worse prognosis. Thus, the detection of lymph node micrometastasis by FHIT and CDKN2A mRNA deletion RT-PCR will be helpful to predict the recurrence and prognosis of patients with completely resected stage I-IIB NSCLC.
淋巴结转移是可切除非小细胞肺癌(NSCLC)的主要预后因素。然而,在淋巴结阴性患者中,完全切除术后复发率为30%-40%,这表明他们的淋巴结分期并不理想。我们旨在评估淋巴结阴性NSCLC患者淋巴结微转移的分子诊断及其预后意义。采用逆转录聚合酶链反应(RT-PCR)对62例已切除的Ⅰ-ⅡB期NSCLC患者的原发性肿瘤样本进行脆性组氨酸三联体(FHIT)和CDKN2A mRNA缺失检测。在49例患者的肿瘤中发现了分子改变。对这49例FHIT或/和CDKN2A缺失肿瘤的NSCLC患者的总共269个淋巴结进行了检查。还对15个阳性对照淋巴结和10个阴性对照淋巴结进行了FHIT和CDKN2A mRNA缺失分析。49例原发性肿瘤中有FHIT和CDKN2A mRNA缺失的患者,分别有39个(22%)和22个(18%)淋巴结存在FHIT和CDKN2A mRNA缺失。淋巴结中FHIT和CDKN2A mRNA缺失的类型与其原发性肿瘤中的类型相同。通过两种标志物联合检测,发现16例患者(32.7%)存在淋巴结微转移。生存分析显示,有淋巴结微转移的患者无病生存率(P = 0.001)和总生存率(P = 0.002)降低。多变量分析表明,淋巴结微转移是预后较差的独立预测因素。因此,通过FHIT和CDKN2A mRNA缺失RT-PCR检测淋巴结微转移将有助于预测完全切除的Ⅰ-ⅡB期NSCLC患者的复发和预后。